ORION CORPORATION PRESS RELEASE 20 MAY 2020 at 12.00 EEST
Sales of darolutamide started in the EU and Japan - Orion receives total of EUR 28 million milestones
Sales of Nubeqa (darolutamide), jointly developed by Orion Corporation and Bayer for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC), has started in the EU and Japan. From the first commercial sales in the EU Orion receives from Bayer a EUR 20 million and from the first commercial sales in Japan a EUR 8 million milestone. Orion will book the milestones in its second quarter 2020 result. The booking has no impact on Orion's outlook for 2020 as the total of EUR 28 million milestones have been included in the financial guidance provided by the company.
Contact person:
Tuukka Hirvonen, Investor Relations and Financial Communications, Orion Corporation
tel. +358 010 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
